SCHEMBL12845746

SCHEMBL12845746

Bc1cc(C(=O)OCC)cnc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ CA12 O43570 3/20 0.47
▸ CA1 P00915 3/20 0.47
▸ CA2 P00918 3/20 0.47
▸ CA7 P43166 3/20 0.47
▸ CA9 Q16790 3/20 0.47
▸ CA14 Q9ULX7 3/20 0.47
▸ ESR1 P03372 1/20 0.43
▸ ESR2 Q92731 1/20 0.43
▸ MAOB P27338 2/20 0.43
▸ LMNA P02545 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ MAOA P21397 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ BRD2 P25440 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12845745 0.85 CYP2C19 (0.51) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL13574604 0.84 CYP2C9 (0.50) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL26412819 0.83 CYP2C9 (0.56) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL277286 0.81 CYP2C9 (0.54) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL28426533 0.81 CA12 (0.57) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL1233369 0.80 CYP2C9 (0.53) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL4731122 0.80 CYP2C9 (0.53) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL17295856 0.80 CYP2C9 (0.53) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL9924655 0.80 CYP2C9 (0.53) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL23714464 0.79 HSD17B2 (0.56) CYP2C9CYP2C19CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053936-A1 SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS ALMIRALL, S.A. (ES) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053936-A1 SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS MAPK1, MAP3K1, MAP3K7 CYP2C9 2080/4885CYP2C19 1543/4885CA12 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback